An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers

• Type: Another Publication in an International Scientific Journal
• Date: 2022

Authors

Santos Gomes, J (Author) Other; Gandra, I (Author) Other; Adao, R (Author) FMUP; Perros, F (Author) Other; Brás-Silva C (Author) FMUP

Journal

Title: Frontiers in Cardiovascular Medicine

Vol. 9

ISSN: 2297-055X

Publisher: Frontiers Media

Indexing

ISI Web of Knowledge - 5 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00W-ZWB

DOI: 10.3389/fcvm.2022.924873

Abstract (EN): Pulmonary arterial hypertension (PAH), also known as Group 1 Pulmonary Hypertension (PH), is a PH subset characterized by pulmonary vascular remodeling and pulmonary arterial obstruction. PAH has an estimated incidence of 15-50 people per million in the United States and Europe, and is associated with high mortality and morbidity, with patients' survival time after diagnosis being only 2.8 years. According to current guidelines, right heart catheterization is the gold standard for diagnostic and prognostic evaluation of PAH patients. However, this technique is highly invasive, so it is not used in routine clinical practice or patient follow-up. Thereby, it is essential to find new non-invasive strategies for evaluating disease progression. Biomarkers can be an effective solution for determining PAH patient prognosis and response to therapy, and aiding in diagnostic efforts, so long as their detection is non-invasive, easy, and objective. This review aims to clarify and describe some of the potential new candidates as circulating biomarkers of PAH.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 26